Microgenesis, founded with a mission to enhance women's fertility potential globally, offers a unique fertility test and personalized nutritional supplementation. Their core service detects subclinical inflammation that impairs ovarian function and implantation, providing a three-month treatment plan tailored to individual needs. Initially targeting women who have failed multiple IVF implantations, Microgenesis is now expanding its market focus to OB-GYNs and direct-to-consumer channels, operating from a CLIA-certified lab in Oakland.

Notable figures affiliated with Microgenesis include experts in reproductive health and biotechnology. The company has garnered attention from key investors in the health tech sector, validating its innovative approach. Microgenesis has achieved significant milestones, including successful case studies demonstrating improved fertility outcomes in challenging cases. The overall impact of Microgenesis lies in its potential to revolutionize fertility treatments, offering hope and effective solutions to women worldwide.